Measuring the effect of elexacaftor/tezacaftor/ivacaftor combination therapy on the respiratory pump in people with CF using dynamic chest radiography.
暂无分享,去创建一个
[1] M. Drumm,et al. Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration , 2021, European Respiratory Journal.
[2] H. Tiddens,et al. The evolving role of radiological imaging in cystic fibrosis , 2021, Current opinion in pulmonary medicine.
[3] T. Hajiro,et al. Prediction of forced vital capacity with dynamic chest radiography in interstitial lung disease. , 2021, European Journal of Radiology.
[4] P. Burgel,et al. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease. , 2021, Respiratory medicine and research.
[5] M. Walshaw,et al. P102 Utility of Dynamic Chest Radiography (DCR) for calculating lung volume subdivisions in adult people with cystic fibrosis , 2021 .
[6] M. Jinzaki,et al. Projected lung areas using dynamic X-ray (DXR) , 2020, European Journal of Radiology Open.
[7] J. Woods,et al. Novel imaging techniques for cystic fibrosis lung disease , 2020, Pediatric pulmonology.
[8] C. Owen,et al. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[9] Z. Kmietowicz. Covid-19: Highest risk patients are asked to stay at home for 12 weeks , 2020, BMJ.
[10] R. Bedi,et al. Utility and validity of dynamic chest radiography in cystic fibrosis (dynamic CF): an observational, non-controlled, non-randomised, single-centre, prospective study , 2020, BMJ Open Respiratory Research.
[11] C. Teneback,et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial , 2019, The Lancet.
[12] L. Lands,et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.
[13] M. Jinzaki,et al. Time-resolved quantitative evaluation of diaphragmatic motion during forced breathing in a health screening cohort in a standing position: Dynamic chest phrenicography. , 2019, European journal of radiology.
[14] M. Jinzaki,et al. Decreased and slower diaphragmatic motion during forced breathing in severe COPD patients: Time-resolved quantitative analysis using dynamic chest radiography with a flat panel detector system. , 2019, European journal of radiology.
[15] E. Ingenito,et al. Tezacaftor–Ivacaftor in Residual‐Function Heterozygotes with Cystic Fibrosis , 2017, The New England journal of medicine.
[16] E. Ingenito,et al. Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del , 2017, The New England journal of medicine.
[17] S. Stanojevic,et al. Physiologic endpoints for clinical studies for cystic fibrosis. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[18] D. Radzioch,et al. Lack of CFTR in Skeletal Muscle Predisposes to Muscle Wasting and Diaphragm Muscle Pump Failure in Cystic Fibrosis Mice , 2009, PLoS genetics.
[19] A. Ionescu,et al. The influence of body composition on respiratory muscle, lung function and diaphragm thickness in adults with cystic fibrosis. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[20] A. Coates,et al. Lung recoil and the determination of airflow limitation in cystic fibrosis and asthma , 1993, Pediatric pulmonology.